NBTX vs. EPIX, FBLG, AQST, PROC, AKBA, VSTM, URGN, XOMA, VNDA, and NLTX
Should you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include ESSA Pharma (EPIX), FibroBiologics (FBLG), Aquestive Therapeutics (AQST), Procaps Group (PROC), Akebia Therapeutics (AKBA), Verastem (VSTM), UroGen Pharma (URGN), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.
Nanobiotix (NASDAQ:NBTX) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.
In the previous week, ESSA Pharma had 3 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for ESSA Pharma and 1 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 1.89 beat ESSA Pharma's score of 0.23 indicating that Nanobiotix is being referred to more favorably in the media.
Nanobiotix's return on equity of 0.00% beat ESSA Pharma's return on equity.
ESSA Pharma received 338 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 76.32% of users gave ESSA Pharma an outperform vote while only 62.50% of users gave Nanobiotix an outperform vote.
Nanobiotix has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500.
Nanobiotix presently has a consensus target price of $11.00, suggesting a potential upside of 66.67%. ESSA Pharma has a consensus target price of $16.50, suggesting a potential upside of 164.42%. Given ESSA Pharma's higher possible upside, analysts plainly believe ESSA Pharma is more favorable than Nanobiotix.
38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 14.7% of ESSA Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ESSA Pharma has lower revenue, but higher earnings than Nanobiotix.
Summary
ESSA Pharma beats Nanobiotix on 8 of the 13 factors compared between the two stocks.
Get Nanobiotix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nanobiotix Competitors List
Related Companies and Tools
